ResearcherKyoto UniversityNo recent work listed
Manabu Muto
Matched on ORCID iD 0000-0002-3127-8203; OpenAlex author ID A5022854492. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 16
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper
Papers 4
- Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicente… Last author DOI 10.1007/s12032-023-02011-y↗
- BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001672↗
- Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Last author DOI 10.18632/oncotarget.24865↗
- Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-015-0864-x↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Masashi Kanai · 4 shared papers, 2016–2023 · strength 0.35
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreati… DOI 10.1097/mpa.0000000000001672↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Tomohiro Kondo · 3 shared papers, 2018–2023 · strength 0.31
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreati… DOI 10.1097/mpa.0000000000001672↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Tadayuki Kou · 3 shared papers, 2016–2023 · strength 0.25
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Paper Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic canc… DOI 10.1007/s10147-015-0864-x↗
- Toshihiko Masui · 3 shared papers, 2016–2023 · strength 0.25
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Paper Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic canc… DOI 10.1007/s10147-015-0864-x↗
- Junichi Matsubara · 2 shared papers, 2020–2023 · strength 0.24
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreati… DOI 10.1097/mpa.0000000000001672↗
- Toshinao Itani · 1 shared paper, 2023 · strength 0.14
- Michio Yoshimura · 1 shared paper, 2023 · strength 0.14
- Kyoichi Takaori · 2 shared papers, 2016–2018 · strength 0.11
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Paper Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic canc… DOI 10.1007/s10147-015-0864-x↗
- Kazuto Nishio · 1 shared paper, 2020 · strength 0.10
- Yuzo Kodama · 1 shared paper, 2018 · strength 0.07
- Tsutomu Chiba · 1 shared paper, 2016 · strength 0.04
- Shinji Üemoto · 1 shared paper, 2016 · strength 0.04
- Shujiro Yazumi · 1 shared paper, 2016 · strength 0.04
- Peng Xue · 1 shared paper, 2016 · strength 0.04
- Akira Kurita · 1 shared paper, 2016 · strength 0.04
- Yuzo Kodama · 1 shared paper, 2016 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.